
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30

<p xmlns="http://www.w3.org/1999/xhtml">
Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DCTH">DCTH</a>), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Conference Call Information</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Event Date: Thursday, August 6, 2026
<br xmlns="http://www.w3.org/1999/xhtml"></br>Time: 8:30 AM Eastern Time

</p><p xmlns="http://www.w3.org/1999/xhtml">
Participant Numbers:
<br xmlns="http://www.w3.org/1999/xhtml"></br>Toll Free: 1-800-717-1738
<br xmlns="http://www.w3.org/1999/xhtml"></br>International: 1-646-307-1865
<br xmlns="http://www.w3.org/1999/xhtml"></br>Webcast: <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FST19CM8EJyF3Np94tJipc8ViMU%3Fdomain%3Dviavid.webcasts.com&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1767384%26amp%3Btp_key%3Dcbc23b55c8&amp;index=1&amp;md5=4aa0f441162a53e0d379f3acd472cb69" shape="rect">https://viavid.webcasts.com/starthere.jsp?ei=1767384&amp;tp_key=cbc23b55c8 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company&#39;s website <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdelcath.com%2Finvestors%2Fevents-presentations%2F&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=b4da7748886f51a7f1360842dff74b41" shape="rect">here</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company&#39;s proprietary products, HEPZATO KIT&#x2122; (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath&#39;s proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hepzatokit.com&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=3&amp;md5=08be4eb3fa5bcb30f5837b2f3c065fa8" shape="rect">Prescribing Information</a>, including BOXED WARNING for the HEPZATO KIT.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260723206368r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260723206368/en/" rel="nofollow">https://www.businesswire.com/news/home/20260723206368/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>ICR Healthcare
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investorrelations@delcath.com" shape="rect">investorrelations@delcath.com</a>

</p>

DCTH

Delcath Systems to Host Second Quarter 2026 Earnings Call

Delcath to Host Q2 2026 Earnings Call and Update Prospects

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Delcath Systems will host a Q2 2026 earnings call on August 6, 2026, potentially driving near-term price action. The update may address HEPZATO KIT and CHEMOSAT adoption in the US and Europe, regulatory context, and early signals on liver-directed chemotherapy performance. Investors will look for guidance or data that could influence valuation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Delcath to discuss Q2 2026 results on Aug 6 conference call.</li><li>Conference call at 8:30 AM ET; dial-in and webcast details.</li><li>HEPZATO KIT and CHEMOSAT details include FDA and European regulatory notes.</li><li>Company focus remains liver cancers; Q2 results may influence near-term sentiment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Delcath Systems, Inc. (DCTH)</strong>: Core company; earnings call to discuss Q2 2026 results; near-term price driver.</li><li><strong>HEPZATO KIT (N/A)</strong>: Delcath’s liver-directed therapy; FDA-regulated; potential driver of revenue/usage.</li><li><strong>CHEMOSAT (N/A)</strong>: Europe device for hepatic perfusion; regulatory status may influence adoption and revenue.</li><li><strong>Melphalan (N/A)</strong>: Chemotherapy component of HEPZATO KIT; regulatory and safety considerations could affect outcomes.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. The announcement is an earnings-call event with product/regulatory context, offering a near-term catalyst and directional risk for DCTH stock tied to Q2 results and adoption signals.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q2 results release date is the key near-term catalyst.</li><li>Any guidance on HEPZATO KIT/CHEMOSAT adoption could re-rate valuation.</li><li>Regulatory/regional context in US/EU may impact narrative.</li><li>Pre-earnings liquidity and small-cap volatility could amplify moves.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Event date: August 6, 2026.</li><li>Second quarter ended June 30, 2026.</li><li>Delcath Systems focuses on liver cancers with HEPZATO KIT and CHEMOSAT.</li><li>HEPZATO KIT: FDA-regulated drug+device; CHEMOSAT: European Class III device.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral near-term; strong Q2 data could trigger a short-term rally.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DCTH">DCTH</a>), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Conference Call Information</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Event Date: Thursday, August 6, 2026
<br xmlns="http://www.w3.org/1999/xhtml"></br>Time: 8:30 AM Eastern Time

</p><p xmlns="http://www.w3.org/1999/xhtml">
Participant Numbers:
<br xmlns="http://www.w3.org/1999/xhtml"></br>Toll Free: 1-800-717-1738
<br xmlns="http://www.w3.org/1999/xhtml"></br>International: 1-646-307-1865
<br xmlns="http://www.w3.org/1999/xhtml"></br>Webcast: <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FST19CM8EJyF3Np94tJipc8ViMU%3Fdomain%3Dviavid.webcasts.com&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1767384%26amp%3Btp_key%3Dcbc23b55c8&amp;index=1&amp;md5=4aa0f441162a53e0d379f3acd472cb69" shape="rect">https://viavid.webcasts.com/starthere.jsp?ei=1767384&amp;tp_key=cbc23b55c8 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company&#39;s website <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdelcath.com%2Finvestors%2Fevents-presentations%2F&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=b4da7748886f51a7f1360842dff74b41" shape="rect">here</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company&#39;s proprietary products, HEPZATO KIT&#x2122; (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath&#39;s proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hepzatokit.com&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=3&amp;md5=08be4eb3fa5bcb30f5837b2f3c065fa8" shape="rect">Prescribing Information</a>, including BOXED WARNING for the HEPZATO KIT.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260723206368r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260723206368/en/" rel="nofollow">https://www.businesswire.com/news/home/20260723206368/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>ICR Healthcare
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investorrelations@delcath.com" shape="rect">investorrelations@delcath.com</a>

</p>

Delcath Systems will host a Q2 2026 earnings call on August 6, 2026, potentially driving near-term price action. The update may address HEPZATO KIT and CHEMOSAT adoption in the US and Europe, regulatory context, and early signals on liver-directed chemotherapy performance. Investors will look for guidance or data that could influence valuation.

News insight

Delcath Systems to Host Second Quarter 2026 Earnings Call

AI summary

Sentiment rationale

Key facts

Earnings